全部文献期刊学位论文会议报纸专利标准年鉴图书|学者科研项目
中外文文献  中文文献  外文文献
作者:... Takahiro Yoneyama , Yasuhiro Hashimoto , Chikara Ohyama
来源:[J].BMC Urology(IF 1.694), 2017, Vol.17 (1)Springer
摘要:Urinary tract obstruction and postoperative hydronephrosis are risk factor for renal function deterioration after orthotopic ileal neobladder construction. However, reports of relationship between transient hydronephrosis and renal function are limited.
作者:... Yuriko Terayama , Tomihisa Funyu , Chikara Ohyama
来源:[J].BMC Urology(IF 1.694), 2017, Vol.17 (1)Springer
摘要:Radical nephrectomy for renal cell carcinoma (RCC) is a risk factor for the development of chronic kidney disease (CKD), and the possibility of postoperative deterioration of renal function must be considered before surgery. We investigated the contribution of the aortic calcific...
作者:... Mitsuki Tanaka , Chikara Ohyama , Yoshihiro Takai
来源:[J].Radiation Oncology(IF 2.107), 2017, Vol.12 (1)Springer
摘要:The purpose of this study was to investigate the differences in the dosimetric advantage of using intraoperatively built custom-linked (IBCL) seeds between permanent iodine-125 (I-125) seed implantation (PI) alone and PI followed by external-beam radiation therapy (EBRT) for pros...
作者:Chikara Ohyama , Yoshimi Tanaka ...
来源:[J].International Journal of Clinical Oncology(IF 1.727), 2017, Vol.22 (6), pp.1087-1093Springer
摘要:The optimal treatment for high-risk prostate cancer (PCa) remains to be established. We previously reported favorable, biochemical recurrence-free survival in high-risk PCa patients treated with a neoadjuvant gonadotropin-releasing hormone agonist or antagonist and estramustine p...
作者:... Yasuhiro Hashimoto , Takuya Koie , Chikara Ohyama
来源:[J].International Journal of Clinical Oncology(IF 1.727), 2017, Vol.22 (2), pp.366-372Springer
摘要:Although quality of life (QOL) is one of the most important considerations in patients treated with anticancer therapies, desirable regimens for neoadjuvant chemotherapy including QOL in locally advanced urothelial carcinoma remain unclear. The present study evaluated the influen...
作者:... Tohru Yoneyama , Yuki Tobisawa , Chikara Ohyama
来源:[J].International Journal of Clinical Oncology(IF 1.727), 2017, Vol.22 (2), pp.214-221Springer
摘要:The application of prostate-specific antigen (PSA) in prostate cancer (PC) screening, diagnosis, and prognosis has improved the clinical management of PC patients. However, the PSA assay has been faced with criticism due to its potential association with over-diagnosis and subseq...
作者:... Tomonori Habuchi , Yoichi Arai , Chikara Ohyama
来源:[J].Medical Oncology(IF 2.147), 2017, Vol.34 (12)Springer
摘要:The aim of the present study was to assess the cost-effectiveness of extended pelvic lymph node dissection (ePLND) compared to neoadjuvant chemohormonal therapy using gonadotropin-releasing hormone agonist/antagonist and estramustine. We retrospectively analyzed data within Michi...
作者:... Takuya Koie , Toshiaki Kawaguchi , Chikara Ohyama
来源:[J].Medical Oncology(IF 2.147), 2017, Vol.34 (6)Springer
摘要:Programmed cell death ligand-1 (PD-L1) is a key target molecule of immunotherapy that is frequently overexpressed in bladder cancer. In the present study, we examined whether PD-L1 expression is associated with clinical outcomes in bladder cancer patients. We enrolled 102 bl...
作者:Chikara Ohyama , Hayato Yamamoto ...
来源:[J].International Urology and Nephrology(IF 1.325), 2017, Vol.49 (5), pp.811-816Springer
摘要:The optimal treatment for high-risk prostate cancer (Pca) remains to be established. We previously reported favorable biochemical recurrence-free survival (BRFS) for high-risk Pca patients treated with neoadjuvant therapy comprising a luteinizing hormone-releasing hormone agonist...
作者:Chikara Ohyama , Akito Yamaguchi ...
来源:[J].World Journal of Urology(IF 2.888), 2017, Vol.35 (11), pp.1737-1744Springer
摘要:To evaluate the impact of lymph node dissection (LND) on clinical outcome during radical nephroureterectomy (RNU) for patients with upper urinary tract urothelial cancer (UTUC).

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×